OncoMatch/Clinical Trials/NCT02064673
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
Is NCT02064673 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Curcumin for prostate cancer.
Treatment: Curcumin — This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage PT1, PT2, PT3
Grade: Gleason 6Gleason 7 (Gleason)
pathologically confirmed T1-T3 disease; pT1-pT3pNxMx; This includes patients with Gleason 6 or 7(T2 disease)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radical prostatectomy
Status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate
Cannot have received: hormone therapy
hormone therapy before surgery
Cannot have received: radiation therapy
radiation therapy as primary treatment after surgery
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^3/uL, platelets ≥ 50 x K/uLL, hemoglobin ≥ 10 g/dL
Kidney function
serum creatinine <2mg/dl
Liver function
bilirubin ≤ 1.5 mg/dl; AST/ALT < 2x ULN
adequate renal and liver function as well as bone marrow reserve (measured serum creatinine <2mg/dl, bilirubin ≤ 1.5 mg/dl, ANC ≥ 1.5 x 10 (3) uL, platelets ≥ 50 x K/uLL, and hemoglobin ≥ 10 g/dL); AST/ALT are equal or greater than 2 times the upper limit of normal [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify